USAID and Takeda Launch Dengue Prevention Campaign

NewsVoir
New Delhi [India], July 26: The United States Agency for International Development (USAID) and Takeda Biopharmaceuticals India Private Limited (formerly Baxalta Bioscience India Private Limited) have launched a new campaign called "Haarega Dengue Haraenge Hum (We Will Together Defeat Dengue)." With changing climate conditions threatening lives, health, economic progress, and straining resilience particularly among the most vulnerable, the campaign in launch phase will focus on educating school children and communities across Maharashtra, Odisha and Uttar Pradesh about how their actions can help prevent dengue. It will also encourage people to adopt habits that can reduce the spread of vector-borne diseases.
Due to the changing climate, specifically a rise in temperature and rainfall, vector-borne diseases are becoming more prevalent, adding additional stress to the already overwhelmed health systems from the recent pandemic. The campaign will look deeper into how climate change affects the spread of infectious diseases and provide strategies to improve preparedness and build stronger and more responsive health systems in the country.
Warren Harrity, Acting Mission Director, USAID, said, "USAID works to increase the resilience of the health systems by focusing on identifying shifts in climate-sensitive, vector-borne diseases through surveillance and early warning; strengthening health system capacity to prepare and respond to climate events; and supporting the development and implementation of climate-smart health policies. USAID is honored to partner with India's local and national health systems, as well as leverage our relationship with corporations like Takeda to detect, prevent, and respond to climate change-related infectious diseases."
Yamashita Yuta, First Secretary (Health Attache), Embassy of Japan in India, stated, "This collaboration for combating dengue represents a significant step in our shared commitment to global health and intensifies the Indo-Japan relationship. Dengue has emerged as a critical threat to public health globally due to the emerged climatic unpredictability, and requires immediate addressal at local and international levels. Through our collective expertise and resources, we can make substantial progress in disease prevention and control, setting an example for international cooperation in healthcare."
Elaborating on the initiative, Annapurna Das, General Manager of Takeda Biopharmaceuticals India Pvt. Ltd., added, "Takeda, as a global pharmaceutical company, believes that bold, collective action is required from all sectors to accelerate efforts in the area of climate change to protect our communities from the impact of vector-borne diseases. Protecting the climate is aligned with our purpose of bringing Better Health and a Brighter Future for all. It's an honour to launch the campaign as we believe that controlling dengue is everyone's responsibility. We are committed to this cause and will continue working with multiple stakeholders including the Government, NGOs, industry, academia and healthcare providers to support the vision of Dengue Mukt Bharat."
Neeraj Jain, Chief Executive Officer, Centre for Health Research and Innovation (CHRI), said, "We are proud to launch the campaign in partnership with Takeda Biopharmaceuticals. Together, we aim to combat dengue by organizing awareness-building campaigns and uniting communities in our commitment to health and climate resilience. As 2024 is promoted as the 'Year of Climate and Health Action,' this partnership emphasizes the need for innovative approaches to fight climate-sensitive, infectious diseases."
The campaign was launched during the "Call to Action for Climate Sensitive Infectious Diseases: a Strategic Synergy Session", an event organized by CHRI under the USAID-supported Sustainable Action for Climate and Health (SACH) Initiative.
This example of the partnership between local organizations, national governments, donors, and private corporations demonstrates the power of collaboration to promote climate-adaptive health systems, workplaces, and communities.
USAID is the U.S. Government's premier international development agency and a catalytic actor driving development results. USAID works to help lift lives, build communities, and advance democracy. USAID's work advances U.S. national security and economic prosperity, demonstrates American generosity, and helps countries progress along their development journey. In India, USAID is collaborating with the country's growing human and financial resources through partnerships that catalyze innovation and entrepreneurship to solve critical local and global development challenges.
To learn more, visit www.usaid.gov/india.
The campaign is part of the broader Sustainable Action for Climate and Health (SACH) Initiative, funded by the United States Agency for International Development (USAID) and implemented by CHRI-PATH aims to promote climate-adaptive health systems, workplaces and communities through partnerships and linkages to products, services and finances. More than 70 organizations have united and are dedicated to this cause.
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
For more information, visit www.takeda.com.
Dengue is a mosquito-borne viral disease that spreads rapidly around the world and was one of the WHO's top 10 threats to global health in 2019. Dengue is primarily transmitted by aedes aegypti mosquitoes and, to a lesser extent, aedes albopictus mosquitoes. It is caused by any of four dengue virus serotypes, each of which can cause dengue fever or severe dengue. The prevalence of individual serotypes varies across different geographies, countries, regions, seasons and over time. Recovery from infection by one serotype provides lifelong immunity against only that serotype, and later exposure to any of the remaining serotypes is associated with an increased risk of severe disease.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by NewsVoir. ANI will not be responsible in any way for the content of the same)